Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Gets Exclusive License For Mochida's Painkiller Drug

This article was originally published in PharmAsia News

Executive Summary

Wyeth has acquired global rights to Mochida Pharmaceutical's preclinical transient receptor potential vanilloid sub-family 1 (TRPV-1) antagonist molecule for treating pain, the companies announced Jan 9. In return, Tokyo-based Mochida will be paid developmental milestones, an up-front fee and royalties on future sales. Full terms of the deal were not disclosed, but Mochida will retain co-development and co-marketing rights in Japan, according to the companies
Advertisement

Related Content

Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
Advertisement
UsernamePublicRestriction

Register

SC066712

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel